Physician profile
Subash Ala
NPI 1053606426
$551.76
in general payments reported to CMS, 2019-2025
10 companies · $85.40 in 2025
The $85.40 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $13.93 · 2021: $27.04 · 2022: $124 · 2023: $46.90 · 2024: $33.64 · 2025: $85.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $136.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $106.35 | 2019-2023 | Xarelto |
| Stryker Corporation | $85.40 | 2025 | Flowtriever |
| E.R. Squibb & Sons, L.L.C. | $69.45 | 2022 | |
| Merck Sharp & Dohme LLC | $38.82 | 2019 | |
| Inari Medical, INC. | $34.74 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $23.63 | 2024 | Kyphon Express II Kyphopak Tray |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.24 | 2021-2024 | Lifevest |
| Vifor Pharma, INC. | $19.60 | 2019 | |
| Glaxosmithkline, LLC. | $17.46 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subash Ala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.